# Acquisition of an Eclipse Tribrid Mass Spectometer System to Advance Proteomics Research in Rhode Island

> **NIH NIH S10** · BROWN UNIVERSITY · 2024 · $1,214,295

## Abstract

PROJECT SUMMARY
The Brown University Proteomics Core Facility seeks to acquire cutting-edge instrumentation to advance
research in cancer biology, aging, neurodegenerative diseases, immunology, and infectious diseases.
Specifically, we propose to acquire an Eclipse Tribrid Mass Spectrometer, Vanquish Neo UHPLC, and FAIMS
Pro Duo Interface through an S10 HEI Grant. This acquisition will benefit major and minor users at Brown
University and the broader research community in Rhode Island in a state designated by the NIH as an IDeA
state identified as needing increased research infrastructure support. The proposed instruments will significantly
enhance the capabilities of our Proteomics Core Facility, enabling advanced, accurate, and precise analysis of
proteins and peptides. The Orbitrap Eclipse Tribrid Mass Spectrometer combines high-resolution mass
spectrometry with sensitivity, speed, and dynamic range. This instrument will enable the identification and
quantification of proteins, post-translational modifications, and protein-protein interactions with unparalleled
precision and accuracy. The Vanquish Neo UHPLC is a high-performance liquid chromatography system that
delivers exceptional separation and resolution. It will allow for efficient sample preparation and increased
throughput for large-scale proteomic experiments at nanoliter amounts. The FAIMS Pro Duo Interface provides
additional selectivity and sensitivity in protein and peptide analysis. It enhances ion separation and increases
the dynamic range of mass spectrometry, enabling the detection of low-abundance peptide species with greater
accuracy. In support of the newly formed Legorreta Cancer Center at Brown, these instruments will benefit
research in cancer biology, where the ability to detect and quantify specific proteins and their modifications is
critical for understanding disease mechanisms and developing new therapies. The instruments will also facilitate
research in the Center on the Biology of Aging, and the Carney Institute for Brain Science, where identifying
disease-related biomarkers from precious samples is essential. In immunology and infectious diseases, the
instruments will enable the identification and quantification of immune system proteins and parasite or pathogen-
derived molecules, aiding in the development of vaccines and therapies. Overall, the acquisition of these
instruments will enhance the Proteomics Core Facility's capabilities and enable cutting-edge research in major
disease areas. The benefits will extend beyond Brown University to the broader research community in Rhode
Island, including undergraduate institutions. This proposal aligns with the NIH's mission to support research that
advances our understanding of disease mechanisms and improves human health.

## Key facts

- **NIH application ID:** 10852717
- **Project number:** 1S10OD036295-01
- **Recipient organization:** BROWN UNIVERSITY
- **Principal Investigator:** ARTHUR Robert SALOMON
- **Activity code:** S10 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,214,295
- **Award type:** 1
- **Project period:** 2024-08-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10852717

## Citation

> US National Institutes of Health, RePORTER application 10852717, Acquisition of an Eclipse Tribrid Mass Spectometer System to Advance Proteomics Research in Rhode Island (1S10OD036295-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10852717. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*